Data & sample collections...
21 collections
We will use nanobody technology as a main vehicle platform for new tracer development as these antibody-fragments have already shown excellent specificity and sensitivity for imaging in oncology and inflammation (De Vos J. et al., 2013; Krasniqi A. e...
This task will be conducted by VUB, VIB together with expertise from Roche, Pfizer and Takeda. Bi-specific constructs will be generated by linking two lowaffinity nanobodies targeting CD8β and CD69 (from Task 3.1) with a genetic spacer into a design ...
Alarmins S100A8 and S100A9 are expressed and secreted by activated phagocytes at the site of inflammation and are known to trigger sterile inflammatory processes. S100A8/S100A9 complexes (calprotectin) are widely used biomarkers for monitoring diseas...
Two 20 amino acid peptide lead sequences that bind to PD-L1 and one lead sequence that binds to PD-1 have been identified, based on the PD-1/PD-L1 binding domain. In recent publications this strategy has been used to design PD-1 or PD-L1 binding pept...
In Task 3.5 we aim to develop new cell labelling techniques that allow radiolabelling of subsets of cells, providing a novel method to validate the in vivo signal of cell-specific tracers in WP4 (Tasks 4.2-4) and cell-based therapies in WP5. With the...
For OI, nanobodies from Tasks 3.1 and 3.2 will be labelled with IRDye800CW. For PET imaging, we will rely on the versatile experience (both preclinical and clinical) in radiolabelling of small proteins and nanobodies within the consortium (see sectio...
Based on results obtained in WP3-5, one or two of the new compounds will be produced under GMP conditions, labelled with a PET-radionuclide or IRDye800CW and tested in a first-in-human study in Task 6.8. The development of peptide tracers will be sup...
All compounds that will be the subject of clinical studies in WP6 will be labelled in a GMP-compliant manner (see section 4 describing radiochemistry experience and availability of techniques at GMP level at the different sites). Transfer of technolo...
Each imaging modality has distinct advantages and disadvantages. While PET, PET/MRI (Judenhofer M.S. et al., 2008), PET/CT, SPECT/CT, OI or OI/CT are superior for whole body tracking of immune cells, the combination of various imaging modalities will...
WP4 will help to select promising lead tracers that are generated in WP3 and immunotracers that are already available. The selection process will be based on in vivo imaging performance parameters, such as pharmacokinetics, retention, non-specific ba...